Delivery Order SPE2DB22D2218-SPE2DB25FR3HD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,196.74 to AmerisourceBergen Drug Corp for CAPLYTA 21 mg capsules (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units) under a firm fixed-price contract valued at $16,991.12. This non-competitive delivery order was issued on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $9,468.39 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,203.19 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 MG capsules (30-count units) on August 28, 2025, with completion by August 29, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a $14,646.30 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed-price, non-set-aside contract with a completion deadline of June 3, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. CAPLYTA is a prescription antipsychotic medication used in the treatment of schizophrenia and bipolar depression, representing the type of...
- The Defense Logistics Agency awarded a $11.89K delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed price, non-set-aside contract with a completion date of July 24, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $43,416.77 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, aligning with AmerisourceBergen's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,244.42 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR3HDDelivery Order
The Defense Logistics Agency awarded a $22,965.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of CAPLYTA 10.5 mg capsules (quantity: 30 units). This is a competitively awarded contract with no set-aside designation, with performance to be completed by September 4, 2025, and fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that provides comprehensive global pharmaceutical support across multiple therapeutic domains for military healthcare programs. CAPLYTA is an atypical antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. Through its expansive prime vendor contract with DLA, AmerisourceBergen Drug Corp supplies a broad portfolio of pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. The company's role as a critical pharmaceutical distributor within the federal medical supply chain reflects its capacity to meet rigorous procurement standards and fulfill time-sensitive healthcare delivery requirements across the Department of Defense and related military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.0k | 9/3/25 |